에 대한 최신 뉴스 GeneDx Holdings (NASDAQ:WGS) 주식

GeneDx Holdings

GeneDx Hldgs

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Uber Weride

Equities

Mid Cap

News

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

NVDA

RXRX

SWTX

TEVA

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

5 Stocks To Watch Heading Into Tuesday

Earnings

Pre-Market Outlook

Markets

LFCR

SPSC

미국 주식 선물이 금요일 아침 (현지 시간 기준) 상승하고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다: 진디엑스 홀딩스(NASDAQ:WGS)는 브라이언 디카이로(Bryan Dechairo)를 COO로 임명했다고 발표했다. 진디엑스 주식은 애프터 마켓에서 2.7% 하락하여 $77.46에 거래되었다.

금요일 주목해야 할 주식: 리소스 커넥션, SPS 커머스, 라이프코어, 진디엑스 및 UDR

GSAT

Topics

AAPL

MDGL

OMCL

PRCT

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 마드리갈 파마슈티컬스(NASDAQ:MDGL)의 주식은 회사가 예상보다 좋은 실적을 발표한 후 51.70% 상승했다.

글로벌스타와 넥스트래커는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 28일-11월 1일)

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings Corp

The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) affirms FY2025 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $2.98 analyst estimate..

Guidance

The Campbell's Affirms FY2025 Adj EPS Guidance of $2.95-$3.05 vs $2.98 Est

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) ("Rivian") today announced that Rivian Holdings, LLC (the "Company"), Rivian, LLC ("Rivian LLC") and Rivian Automotive, LLC ("Rivian Automotive" and, together with the Company and Rivian LLC, the "Co-Issuers") intend to offer, subject to market and other customary conditions, $1,250,000,000 aggregate principal amount of senior secured green notes due 2031 (the "notes") in a private offering. Rivian expects to use the net proceeds from the offering of the notes, together with cash on hand, to redeem in full the $1,250,000,000 aggregate principal amount of the Co-Issuers' outstanding floating rate senior secured notes due 2026 (the "2026 Notes") and pay related fees and expenses. This press release does not constitute a notice of redemption with respect to the 2026 Notes.
The notes are expected to be guaranteed by each of the Company's subsidiaries that also guarantee the Co-Issuers' senior secured asset-based revolving credit facility (the "ABL Facility"). The notes and the guarantees are expected to be secured on a first-priority basis by substantially all assets of the Co-Issuers and the guarantors, other than ABL Priority Collateral (as defined below), if and when the previously announced loan facility with the Department of Energy is funded, on a first-priority basis by substantially all assets of Rivian New Horizon, LLC, and on a second-priority basis by the inventory, receivables, certain deposit accounts and certain related assets (which exclude intellectual property) which secure the ABL Facility on a first-priority basis (the "ABL Priority Collateral"), in each case subject to certain excluded assets and permitted liens.

RIVN

Rivian Automotive Intends To Offer $1.25B Senior Secured Green Notes Offering To Refinance Outstanding Senior Secured Notes due 2026

Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.66 by 10.61 percent. This is a 2.67 percent decrease over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $2.48 billion which beat the analyst consensus estimate of $2.43 billion by 1.83 percent. This is a 4.47 percent increase over sales of $2.37 billion the same period last year.

Earnings Beats

Campbell Soup Q3 Adj. EPS $0.73 Beats $0.66 Estimate, Sales $2.48B Beat $2.43B Estimate

Truist Securities analyst Matthew Coad initiates coverage on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Sell rating and announces Price Target of $60.

Price Target

Initiation

Analyst Ratings

Truist Securities Initiates Coverage On Block with Sell Rating, Announces Price Target of $60

TradePulse Alert Confirms Early Up Move in LLY
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/30203153/Screenshot-2025-05-30-at-4.23.48%E2%80%AFPM-992x1024.png" alt="" class="wp-image-13683" /></figure>
Eli Lilly (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:24 AM on May 30th, a significant trading signal occurred for Eli Lilly (LLY) as it demonstrated a Power Inflow at a price of $734.98. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Lilly's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Lilly's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for LLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $734.98. The returns on the High price ($745.93) and Close price ($737.87) after the Power Inflow are respectively 1.5% and 0.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

WIIM

Technicals

Opinion

Signals

Eli Lilly Rises 1.5% After Key Trading Signal

Nokia and Andorix partner to accelerate Private 5G and Edge solutions in North American real estate market&nbsp;
<ul>
<li>Private 5G, Neutral Host Network and Edge Application OT solutions enabled by Nokia Digital Automation Cloud (DAC) to enable efficient building operations and improve tenant's satisfaction.&nbsp; &nbsp;</li>
</ul>

Nokia Teams Up With Andorix To Expand Indoor 5G and Edge Solutions Across U.S. And Canadian Properties

~ Alignment with FDA continues to support Accelerated Approval pathway ~
~ BLA submission planned for first quarter of 2026 ~
~ Conference call today at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KJrUuvgpMd-Ddja3YfjTaW-sEFYSuEc8TNCL8DhDuaFHTkrvl5gSZYYVlr1J5ubOEYW0Znoht2JKxs4d8ldSNg==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis plan and Chemistry, Manufacturing and Controls (CMC) information that will support a Biologics License Application (BLA) submission expected in the first quarter of 2026.
Statistical Analysis Plan
In the second quarter of 2025, the Company held a Type B meeting with the FDA to discuss the proposed use of external control data and the prospectively defined statistical analysis plan (SAP) in support of the planned BLA submission for AMT-130. The FDA continued to support its prior agreement that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval. The FDA agreed that the primary efficacy analysis for the BLA will evaluate the 3-year change in cUHDRS in high-dose AMT-130 patients compared to a propensity score-adjusted external control arm. The Company plans to use propensity score-weighted external control derived from the ENROLL-HD dataset for the primary analysis and to submit certain sensitivity analyses, including one using a propensity score-matched external control, as additional support.
The FDA also agreed that ENROLL-HD – a large, prospective, longitudinal, natural history study of patients with Huntington's disease – may be acceptable as the external control dataset for the primary analysis of the trial data along with additional sensitivity analyses using the TRACK-HD/TRACK-ON and PREDICT-HD datasets. To date, approximately 33,000 patients have enrolled in ENROLL-HD. Compared to previously used natural history studies like TRACK-HD and PREDICT-HD, ENROLL-HD offers a substantially larger sample size, lower attrition rates, and longer average patient follow-up. The Company expects the larger sample size to reduce variability in the external control data and enhance the robustness of the SAP.
The Company plans to submit an updated SAP consistent with discussions from the recently held Type B meeting to the FDA in the second quarter of 2025.
Chemistry, Manufacturing and Controls (CMC)
In the first quarter of 2025, the Company held a Type B meeting with the FDA to discuss CMC requirements in support of the planned BLA submission for AMT-130. The FDA agreed that validation of the AMT-130 manufacturing process should be possible using experience and prior knowledge from the etranacogene dezaparvovec-drlb (HEMGENIX&#xAE;) process, complemented with additional full-scale AMT-130 GMP batches and a single Process Performance Qualification (PPQ) batch.
The FDA also agreed with the Company's proposed drug product release testing plan, including the proposed potency assay, pending completion of qualification and specification setting activities.
Next Steps for the Planned BLA Submission
Based on these recent Type B meetings with the FDA, the Company continues to prepare for a BLA submission for AMT-130 in the treatment of Huntington's disease. Certain key next steps and expected timing include:
<ul>
<li>Q2 2025: submit updated SAP to the FDA &nbsp;</li>
<li>Q3 2025: initiate PPQ run and present topline Phase I/II data per the SAP &nbsp;</li>
<li>Q4 2025: hold pre-BLA meeting with the FDA &nbsp;</li>
<li>Q1 2026: submit BLA with a request for priority review designation &nbsp;</li>
</ul>

QURE

uniQure Secures FDA Alignment On AMT-130, Targeting 2026 BLA Submission

Asset Sales

Dow Announced That It Has Signed A Sale And Purchase Agreement To Sell Its 50% Interest In Dowaksa Advanced Composites Holdings Bv (Dowaksa) To Aksa Akrilik Kimya Sanayii A.Ş For Proceeds Of $125M

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), often dubbed China&#8217;s Tesla, announced its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45711427/nio-inc-provides-may-2025-delivery-update" rel="noreferrer noopener">May 2025 delivery results</a> on Monday.
NIO delivered 23,231 vehicles in May 2025, an increase of 13.1% year-over-year. The company&#8217;s newer brands, ONVO and FIREFLY, played a significant role in this growth.
The deliveries comprised 13,270 vehicles from the company&#8217;s premium smart electric vehicle brand NIO, 6,281 vehicles from the company&#8217;s family-oriented smart electric vehicle brand ONVO, and 3,680 vehicles from the company&#8217;s small smart high-end electric car brand FIREFLY.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply" rel="noreferrer noopener">Alibaba And Baidu Turn To Chinese AI Chips As US Sanctions Squeeze Nvidia Supply</a>
Year-to-date, NIO has delivered a total of 89,225 vehicles in 2025, marking a 34.7% increase year-over-year, the company said in a press release.
As of May 31, 2025, cumulative deliveries for the company have reached 760,789 vehicles.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) experienced a <a target="_blank" href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report" rel="noreferrer noopener">decline in sales</a> in China compared to rivals like&nbsp;NIO, Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>),&nbsp;Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and&nbsp;BYD Co., which posted strong growth in May.
NIO stock is down over 22% and 34% in the last 12 months. It grappled with&nbsp;challenges in achieving full-year profitability, primarily due to high research and development expenses and significant operational costs.
Trump administration&#8217;s tariff policies posed additional headwinds.
On May 12, Beijing and Washington <a href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" target="_blank" rel="noreferrer noopener">agreed to lower tariffs</a> on each other&#8217;s products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China&#8217;s 125% duties on U.S. goods will drop to 10% for 90 days.
Price Actions: NIO stock is trading higher by 1.98% to $3.61 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45679204/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">Apple iPhone Shipment Could Decline In 2025 As Tariff, Competition Play Spoil Sport: IDC</a></li>
</ul>
Photo by Tada Images via Shutterstock

Asia

Tech

TSLA

XPEV

China's NIO Clocks 13% Deliveries Growth In May, Tesla Lags

Pharmacokinetics (PK)
KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorption was demonstrated with a median tmax of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing and steady-state was achieved by Day 4.
Pharmacodynamics (PD)
KT-621 demonstrated rapid, deep and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
STAT6 levels in blood and skin were measured using a highly sensitive and quantitative mass spectrometry assay. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or when most subjects' STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both.
In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching &gt;90% across all SAD doses starting at 6.25 mg. All SAD cohorts at doses of 75 mg or greater achieved &gt;95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects.
In MAD, robust STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg. Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg with recovery starting as early as 4 days post-last dose.
In MAD, robust STAT6 degradation was observed in skin at the first timepoint measured (Day 7) for doses above 1.5 mg. Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg.
Th2 Biomarkers
The impact of STAT6 degradation on Th2 biomarkers was assessed in the MAD cohorts, despite the low baseline levels typically seen in healthy volunteers. TARC reduction was observed for all KT-621 dose groups, with median reduction of up to 37% at Day 14. We believe these results are comparable or superior to what was seen in the dupilumab healthy volunteer study. In line with the dupilumab study in healthy volunteers, minimal IgE reductions were observed given the low levels of IgE at baseline and the short duration of treatment. Eotaxin-3, a highly specific downstream cytokine of the IL-4/IL-13 pathway, was also measured. Eotaxin-3 reduction was observed for all KT-621 dose groups with a median reduction of 63% at Day 14. These results are superior to what has been reported with dupilumab in asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) patients even at 52 weeks.
Safety and Tolerability
The safety profile of KT-621 was undifferentiated from placebo. There were no serious adverse events (SAEs), no severe AEs, no treatment related adverse events (TRAEs) in more than one subject, no TRAEs leading to discontinuation, and no clinically relevant changes in vital signs, laboratory tests and ECGs.
Next Steps
The Company's KT-621 BroADen Phase 1b trial in moderate to severe AD patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in AD and asthma are planned to start in 4Q25 and 1Q26, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.

Biotech

Health Care

General

KYMR

Kymera Therapeutics Announced Clinical Results From The Phase 1 Healthy Volunteer Study Of KT-621

BCRX

BioCryst To Present New ORLADEYO Data At 2025 EAACI Meeting, Highlighting HAE Prophylaxis In Adults and Children

AngloGold Ashanti plc ("AngloGold Ashanti", "AGA" or the "Company") has agreed to sell its interest in Mineração Serra Grande mine ("MSG") located in the state of Goiás, Brazil, to Aura Minerals Inc. ("Aura").
The Company will sell Mineração Serra Grande S.A. ("Sale"), which owns MSG to a Brazilian incorporated affiliate of Aura ("Purchaser") for the following consideration:
<ul>
<li>A cash consideration of $76 million on closing subject to certain working capital adjustments as at the closing date; and</li>
<li>Deferred Consideration Payments equivalent to a 3% net smelter returns participation over the current Mineral Resource of MSG inclusive of the Mineral Reserve – these Deferred Consideration Payments will be paid quarterly in cash.</li>
</ul>
The recent focus at MSG has been on stabilizing the operations including the decommissioning of the legacy tailings storage facility ("TSF Decharacterization") which is nearing completion. However, MSG remains one of AGA's higher cost and its smallest operation by production.
"This sale ensures we further sharpen our focus on capital allocation, operating efficiencies and the optimization of our portfolio," said AngloGold Ashanti CEO Alberto Calderon. "We've also worked hard to ensure that MSG and its excellent team joins an established company which will continue to be responsible stewards of this asset for the benefit of all stakeholders."
The Sale excludes certain subsidiaries of Mineração Serra Grande S.A which hold assets that do not form part of MSG's mining operations and include properties. These will remain in the AGA group and will be transferred from under Mineração Serra Grande S.A. by means of a spin-off prior to closing ("MSG Subsidiaries Transfer").
The Disposal is subject to the fulfilment of the following conditions:
i. Anti-trust approval from the Brazilian authorities (CADE); ii. The completion of the TSF Decharacterization work; iii. The completion of the MSG Subsidiaries Transfer; and iv. No Material Adverse Event occurring prior to closing.
It is expected that all the conditions will be fulfilled, and the Sale is expected to close during Q3 2025.

AngloGold Sells Brazil Mine to Aura Minerals for $76M, Plus Future Royalties

NBIS

Nebius Invests In ClickHouse Series C To Unlock Value And Fuel AI Infrastructure Expansion

JBIO

Jade Biosciences Announced New Preclinical Data On JADE101, Its Anti-april Monoclonal Antibody Being Developed For The Treatment Of IgA Nephropathy (IgAN)

A. New proteoElute nanoflow nLC system features ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology
B. Introducing new generation of PepSep Advanced nLC columns to further improve chromatographic resolution, sensitivity and proteomics identifications
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263257&amp;newsitemid=20250602715993&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=17d2f94ec69b3f1e87b36b18a38df92a">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.

BRKR

Bruker Launches proteoElute nanoLC System, Advancing Ultra-Sensitive Proteomics

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439734-1&amp;h=3498642422&amp;u=https%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.">Trevi Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), is pleased to announce today positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54 mg BID and 27 mg BID dose groups achieved reductions from Baseline of 60.2% (p&lt;0.0001), 53.4% (p&lt;0.0001), and 47.9% (p&lt;0.01), respectively, compared to a placebo reduction from Baseline of 16.9%1.&nbsp;Statistically significant improvements were observed across&nbsp;secondary endpoints at Week 6 in the 108 mg BID and 54 mg BID dose groups.

TRVI

Trevi's Cough Drug Haduvio Shows Results in IPF Patients, Cutting Coughs by Over 60%

SCIEX And Evosep Sign Reseller Agreement To Expand Access To Standardized High-Throughput Proteomics For Pharma And Biotech

ZLAB

Zai Lab Limited Announced That Updated Data From An Ongoing, Global Phase 1A/1B Clinical Trial (NCT06179069) Evaluating Zocilurtatug Pelitecan, Or Zl-1310, The Company's Potential First-in-class, Delta-like Ligand (DLL3) Antibody-drug Conjugate (ADC) For Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Breakthrough Athena Ion Processor (AIP) delivers up to 35% more peptide and 20% more protein identifications for highest sensitivity proteomics
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263258&amp;newsitemid=20250602810313&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=7ec8a18c42acb3ef4e62e11c4e05f4ab">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced significant further advances in ultra-high sensitivity 4D-Proteomics&#x2122; with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF&#xAE; methods for key biological and clinical research problems with very low sample amounts.

Bruker Unveils New timsUltra AIP System With Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics And Metaproteomics

Guardant Health Announced That The Results Of The Phase III SERENA-6 Trial - Sponsored By Astrazeneca - Demonstrate The Clinical Value Of The Guardant360 Cdx Test In A Circulating Tumor DNA-guided Approach To Detect And Treat Emerging Resistance In 1St-line Therapy Ahead Of Radiological Disease Progression In Breast Cancer

Press Releases

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

GeneDx Announces Completion of Fabric Genomics Acquisition

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

GeneDx to Participate in Upcoming Investor Conferences

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

Hinge Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Hldgs

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Option Care Health

OPKO Health

Premier

Pennant Gr

Privia Health Gr

RadNet

Jefferies

TD Securities

Wells Fargo

Goldman Sachs

TD Cowen

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 위라이드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.
2. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식이 43.45% 상승했다. 이는 트럼프 대통령이 중국에서 오는 $800 이하의 소포에 대한 관세를 연기했다고 보도된 후 발생한 일이다. 또한, 중국의 딥시크(DeepSeek) AI 모델에 대한 낙관론도 최근 주가를 끌어올렸다.
3. 스프링웍스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>)의 주식이 42.58% 상승했다. 이는 머크 그룹(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>)가 회사를 인수하기 위한 고급 논의를 진행 중이라고 발표한 후 발생한 일이다.
4. 리커젼 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)의 주식이 40.59% 증가했다.
5. 세이블 오프쇼어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>)의 주식이 39.09% 상승했다.
6. 진DX 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식이 28.23% 상승했다. 이는 회사가 울트라래피드 전장유전체 시퀀싱(UltraRapid Whole Genome Sequencing)을 발표하여 48시간 내에 실행 가능한 결과를 제공한다고 발표한 후 발생한 일이다.
7. 브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)의 주식이 28.22% 상승했다. 이는 지난 주 중국의 딥시크 AI 모델과 관련된 AI 경쟁 우려로 하락한 후 반등 가능성이 제기된 것으로 보인다.
8. 인스페리티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>)의 주식이 25.99% 증가했다. 이는 회사가 예상보다 좋은 4분기 결과를 발표한 후 발생한 일이다.
9. 크리스퍼 테라퓨틱스 AG(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)의 주식이 25.21% 상승했다. 이는 회사가 예상보다 좋은 4분기 재무 결과를 발표한 후 여러 애널리스트들이 주가 전망을 상향 조정한 후 발생한 일이다.
10. 액섬 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)의 주식이 24.01% 상승했다. 이는 회사가 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)과의 모든 특허 소송을 해결하기 위한 합의에 도달한 후 발생한 일이다. 여러 애널리스트들이 주가 전망을 상향 조정했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%9D%B8%ED%85%94-%EC%95%8C%EB%A6%AC%EB%B0%94%EB%B0%94-%EB%B0%8F-cvs-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%83%81%EC%8A%B9%ED%95%9C-12/" target="_blank" rel="noopener">슈퍼 마이크로, 인텔, 알리바바 및 CVS 등 지난주 상승한 12개 대형주 (2월 10일-2월 14일)</a>
<a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B3%A0%EB%8C%80%EB%94%94-%EB%B0%8F-%ED%8A%B8%EB%A0%88%EC%9D%B4%EB%93%9C-%EB%8D%B0%EC%8A%A4%ED%81%AC%EB%8A%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-11/" target="_blank" rel="noopener">레딧, 고대디 및 트레이드 데스크는 등 지난주 하락한 11개의 대형주 (2월 10일~2월 14일)</a>
사진 출처: WeRide
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식 선물이 금요일 아침 (현지 시간 기준) 상승하고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다:
<ul>
<li>진디엑스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)는 브라이언 디카이로(Bryan Dechairo)를 COO로 임명했다고 발표했다. 진디엑스 주식은 애프터 마켓에서 2.7% 하락하여 $77.46에 거래되었다.</li>
<li>라이프코어 바이오메디컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>)는 목요일 2분기 실적을 발표했으며, 예상보다 나은 결과를 기록했다. 이 회사는 주당 25센트의 분기 손실을 보고했으며, 시장 예상치인 29센트의 손실보다 양호한 결과이다. 또한, 이 회사는 3,260만 달러의 분기 매출을 보고했으며, 이는 애널리스트 컨센서스 예상인 2,975만 달러를 초과한 수치이다. 라이프코어 바이오메디컬 주식은 애프터 마켓에서 5.3% 상승하여 $7.01에 거래되었다.</li>
<li>SPS 커머스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>)는 카본6 테크놀로지스(Carbon6 Technologies Inc.)를 인수하기로 합의했다. SPS 커머스 주식은 목요일에 0.6% 하락하여 $182.81에 거래되었다.</li>
</ul>
프리마켓 보도를 확인하려면 <a href="https://www.benzinga.com/premarket/">여기</a>를 클릭하세요.
<ul>
<li>리소스 커넥션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGP#NASDAQ">RGP</a>)는 2분기 실적이 긍정적이라고 발표했다. 이 회사는 주당 18센트의 분기 이익과 1억 4,560만 달러의 매출을 보고했다. 리소스 커넥션 주식은 애프터 마켓에서 3.2% 상승하여 $9.00에 거래되었다.</li>
<li>UDR(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>)는 마이크 레이시(Mike Lacy)를 COO로 승진시키고 새로운 CFO를 채용하기 위한 임원 검색 프로세스를 시작할 계획이라고 발표했다. UDR 주식은 목요일에 2% 하락하여 $42.53에 거래되었다.</li>
<li></li>
</ul>
다음도 확인해 보세요: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티브랜즈 주식으로 1분기 실적 발표 전 매달 $500를 버는 방법</a></li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 마드리갈 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41648647" target="_blank" rel="noreferrer noopener">예상보다 좋은 실적</a>을 발표한 후 51.70% 상승했다.
2. 프로셉트 바이오로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41583831" target="_blank" rel="noreferrer noopener">예상보다 좋은 3분기 재무 실적</a>과 2024 회계연도 매출 가이던스를 상향 조정했다고 발표한 후 34.20% 상승했다. 또한, 한 주주가 주당 91달러에 보통주 1억 7,500만 달러를 공모했다.
3. 글로벌스타(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>)의 주식은 회사가 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)과의 서비스 계약을 수정하여 새로운 위성과 인프라로 확장된 MSS 네트워크를 출시한다고 발표한 후 33.98% 상승했다.
4. 진Dx 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)의 주식은 회사가 예상보다 좋은 실적을 발표하고 <a href="https://www.benzinga.com//node/41602881" target="_blank" rel="noreferrer noopener">2024 회계연도 매출 가이던스를 상향 조정</a>한 후 31.17% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/wgs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
5. 넥스트래커(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>)의 주식은 회사가 2분기 실적을 발표하고 2025 회계연도 GAAP <a href="https://www.benzinga.com//node/41635816" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 상향 조정</a>한 후 25.91% 상승했다.
6. V.F. 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>)의 주식은 회사가 2분기 재무 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/41599918" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>한 후 25.82% 상승했다. 이 회사는 팀버랜드(Timberland)의 모기업이다.
7. 옴니셀(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>)의 주식은 회사가 3분기 실적을 발표하고 2024 회계연도 가이던스를 <a href="https://www.benzinga.com//node/41619987" target="_blank" rel="noreferrer noopener">예상치 이상으로 상향 조정</a>한 후 23.22% 상승했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/omcl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EB%B0%8F-%EC%97%90%EC%8A%A4%ED%8B%B0-%EB%A1%9C%EB%8D%94%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">슈퍼 마이크로 및 에스티 로더는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EB%A1%9C%EB%B8%94%EB%A1%9D%EC%8A%A4-%EB%B0%8F-%EA%B0%80%EB%AF%BC%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

진Dx 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)가 월요일 시장 마감 후 1분기 재무 결과를 보고한 후 주가가 급등했다. <a href="https://www.benzinga.com/pressreleases/24/04/g38502059/genedx-reports-first-quarter-2024-financial-results-and-business-highlights" target="_blank" rel="noopener">주요 내용</a>을 살펴보자.
주요 사항 (The Details): 진Dx(GeneDx)는 분기 손실을 주당 33센트로 보고했는데, 이는 분석가의 합의 손실 추정치인 67센트를 50.75%나 앞선 것이다.
이 회사는 분기별 매출이 6,242만 2,000달러로 분석가 합의 추정치인 4,946만 3,000달러를 26.2% 상회했으며 지난해 같은 기간보다 매출 4,313만 9,000달러보다 44.7% 증가한 수치라고 보고했다.
&#8220;우리의 강력한 1분기 실적은 엑솜(exome) 및 게놈(genome) 매출 증가, 평균 환급률 증가, 테스트에 대한 접근성 확대, 의미 있는 현금 소모 감소라는 세 가지 주요 조직 초점에 대한 우리의 지속적인 헌신을 반영한다&#8221;고 진Dx 의 CEO인 Katherine Stueland가 말했다.
&#8220;우리 팀의 1분기 성공적인 실행은 2024년 연간 매출 지침을 2억 3,500만~2억 4,500만 달러로 높이고 2025년에 수익성을 달성하겠다는 우리의 기대를 되풀이할 수 있다는 확신을 주었다.&#8221;
전망 (Outlook):  진Dx는 2024년 연간 매출 지침을 2억 2천만 달러-2억 3천만 달러에서 2억 3,500만-2억 4,500만 달러로 상향 조정했으며, 2024년 전체 조정 총 마진 프로필을 최소 50%에서 최소 60%로 확장했다.
관련 뉴스: <a href="https://www.benzinga.com/news/24/04/38499888/whats-going-on-with-super-micro-computer-stock-ahead-of-earnings">기업 실적 발표 전 슈퍼 마이크로 컴퓨터 주식의 동향</a>
WGS 주가 움직임: 진Dx의 주가는 월요일 시간 외 거래에서 30.18% 급등한 14.32달러에 거래되었다.
사진: Pixabay의 Gerd Altmann

진DX: 예상보다 좋은 1분기 실적 및 연간 전망 상향 조정 후 주가 급등

Comments

GeneDx Holdings

뉴스

에 대한 최신 뉴스 GeneDx Holdings (NASDAQ:WGS) 주식

일요일, 2월 16, 2025

금요일, 1월 03, 2025

일요일, 11월 03, 2024

화요일, 4월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌